<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clonazepam: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clonazepam: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clonazepam: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9284" href="/d/html/9284.html" rel="external">see "Clonazepam: Drug information"</a> and <a class="drug drug_patient" data-topicid="12282" href="/d/html/12282.html" rel="external">see "Clonazepam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F49069737"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk from concomitant use with opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including clonazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing clonazepam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The continued use of benzodiazepines, including clonazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam after continued use may precipitate acute withdrawal reactions, which can be life threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam or reduce the dosage.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F153382"><span class="drugH1">Brand Names: US</span>
<ul>
<li>KlonoPIN</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866393"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-ClonazePAM;</li>
<li>Clonapam;</li>
<li>PMS-ClonazePAM;</li>
<li>PMS-ClonazePAM-R;</li>
<li>PRO-ClonazePAM;</li>
<li>RIVA-ClonazePAM;</li>
<li>Rivotril;</li>
<li>TEVA-ClonazePAM [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051776"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Benzodiazepine</span>;</li>
<li>
<span class="list-set-name">Benzodiazepine</span></li></ul></div>
<div class="block dop drugH1Div" id="F153404"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing presented as mg/kg and a fixed mg dose; use caution. When dividing daily doses, may consider administering largest dose at bedtime to reduce somnolence.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9bf68a7-b72e-4fb1-a758-32dd24ad7dea">Neuroirritability, agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroirritability, agitation (palliative care): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;30 kg: Oral: Initial: 0.01 to 0.03 mg/kg/day in divided doses up to 3 to 4 times daily; increase dose to desired effect up to a maximum daily dose: 0.2 mg/kg/<b>day</b> in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ullrich.1','lexi-content-ref-17933619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ullrich.1','lexi-content-ref-17933619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">≥30 kg: Oral: Initial: ≤0.25 mg/dose 3 times daily; may increase by 0.5 to 1 mg/day every 3 days up to maintenance dose range: 0.05 to 0.2 mg/kg/day up to maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ullrich.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder: </b>Adolescents ≥18 years: Oral: Initial: 0.25 mg twice daily; increase in increments of 0.125 to 0.25 mg twice daily every 3 days; target dose: 1 mg/day in divided doses; some patients may require higher doses up to a maximum daily dose of 4 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9db011b-803f-47ad-99d4-9caa132ee9f6">Seizures, Lennox-Gastaut syndrome, akinetic, myoclonic, and absence; maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, Lennox-Gastaut syndrome, akinetic, myoclonic, and absence; maintenance therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Clonazepam should be reserved for refractory cases and possibly in combination with other antiepileptic agents; clonazepam use as initial therapy has been replaced by newer agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898971','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898971','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;10 years or ≤30 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.01 to 0.03 mg/kg/day in 2 to 3 divided doses; maximum initial daily dose: 0.05 mg/kg/<b>day</b>; increase in 0.01 to 0.02 mg/kg/day increments (not to exceed range of 0.25 to 0.5 mg depending on patient); titrate dose every 2 or 3 days until seizures are controlled or adverse effects observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mikati.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mikati.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: 0.05 to 0.2 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 0.2 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mikati.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mikati.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years or &gt;30 kg and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.01 to 0.05 mg/kg/day in 2 or 3 divided doses; maximum initial dose: 0.5 mg/dose 3 times daily; may increase dose by 25% or by 0.5 to 1 mg every 3 to 7 days until seizures are controlled or adverse effects observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-Mikati.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-Mikati.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose range: 0.05 to 0.2 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-Mikati.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-Mikati.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="265ce1dd-5171-4e7c-91bb-f5659e049597">Seizures, rescue therapy of prolonged seizures and cluster seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, rescue therapy of prolonged seizures and cluster seizures:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents: Orally disintegrating tablet (ODT): Oral: 0.01 to 0.03 mg/kg/dose; maximum dose: 2 mg/dose; round dose up to nearest ODT tablet size (eg, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg); in appropriate patients (clinician decision), may consider repeating dose after at least 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35971024','lexi-content-ref-20413800','lexi-content-ref-24908194','lexi-content-ref-31208784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35971024','lexi-content-ref-20413800','lexi-content-ref-24908194','lexi-content-ref-31208784'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> There is currently no standard method for the withdrawal of clonazepam in pediatric patients. In general, avoid abrupt discontinuation; gradually withdraw. Successful discontinuation of an antiseizure medication is dependent on several factors, including but not limited to: Time of seizure freedom, underlying reason for the seizures, neuroimaging abnormalities, underlying neurodevelopmental status, and medication to be withdrawn (including dose, duration of therapy, and other pharmacokinetic/dynamic considerations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990368'])">Ref</a></span>). For other uses of clonazepam, unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826'])">Ref</a></span>). When managing panic disorder in adolescents ≥18 years, the manufacturer suggests decreasing the dose by 0.125 mg twice daily every 3 days until medication withdrawn.</p></div>
<div class="block dorp drugH1Div" id="F51090548"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution (has not been studied in pediatric patients); titrate based on tolerability and response; in adults, due to &lt;2% eliminated in the urine as unchanged drug, no dosage adjustment suggested with kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F51090549"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Clonazepam undergoes hepatic metabolism. Contraindicated in patients with significant hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F153387"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9284" href="/d/html/9284.html" rel="external">see "Clonazepam: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise). Avoid use in patients with a history of substance use, misuse of medications, or depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anxiety and agitation, acute (adjunctive therapy or monotherapy) (off-label use):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.5 mg/day in 2 divided doses; may be given as needed or scheduled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22233697','lexi-content-ref-Marder.1','lexi-content-ref-Mojtabai.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22233697','lexi-content-ref-Marder.1','lexi-content-ref-Mojtabai.1','lexi-content-ref-manu.1'])">Ref</a></span>). May increase dose based on response and tolerability up to 4 mg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roy-Byrne.2020b','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roy-Byrne.2020b','lexi-content-ref-manu.1'])">Ref</a></span>). In severe agitation due to psychosis, some experts consider further increasing dose, if needed and tolerated, up to a reported maximum of 8 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22233697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22233697'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anxiety disorder (adjunctive therapy or monotherapy) (alternative agent):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> While FDA-approved for panic disorder, clinical trials also support use in other anxiety disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24399428','lexi-content-ref-27121429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24399428','lexi-content-ref-27121429'])">Ref</a></span>). Generally used short-term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitors) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term, low-dose therapy (eg, 0.25 mg/day) may be considered in select patients when other treatments are ineffective or poorly tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161'])">Ref</a></span>). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADoD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADoD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>Oral: </b>0.25 to 1 mg/day in 1 to 2 divided doses; may be given as needed or scheduled. If needed, may increase daily dose based on response and tolerability in increments of 0.25 to 0.5 mg every few days (eg, ≥3 days); usual target range: 1 to 3 mg/day in 1 to 4 divided doses; maximum: 4 mg/day. To minimize daytime motor impairment and drowsiness, may be taken as a single dose at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roy-Byrne.2020a','lexi-content-ref-Roy-Byrne.2020b','lexi-content-ref-Stein.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roy-Byrne.2020a','lexi-content-ref-Roy-Byrne.2020b','lexi-content-ref-Stein.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6c2bbcf-95a4-427d-aa7f-ab71434ed104">Myoclonus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myoclonus (monotherapy or adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 mg/day in 2 divided doses; may gradually increase daily dose based on response and tolerability to a usual dose of 1.5 to 3 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caviness.2020','lexi-content-ref-3753263','lexi-content-ref-2499399','lexi-content-ref-9168167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caviness.2020','lexi-content-ref-3753263','lexi-content-ref-2499399','lexi-content-ref-9168167'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8b882a6-562b-4271-8b80-4e9bee8b8c8c">Rapid eye movement sleep behavior disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid eye movement sleep behavior disorder (monotherapy or adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.25 to 0.5 mg within 30 minutes of bedtime; usual dose range: 0.25 to 1 mg before bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36515157','lexi-content-ref-35141811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36515157','lexi-content-ref-35141811'])">Ref</a></span>). If well tolerated, experts suggest higher doses may be considered in absence of response; however, maximum dose is not defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36515157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36515157'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with cognitive impairment, advanced neurodegenerative disease, or gait disorders, avoid use or reduce dose (eg, initial dose: 0.125 to 0.25 mg before bedtime) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howell.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howell.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7f1b582-32d5-4f4f-a358-a6ec5f0bfc20">Seizure disorders, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure disorders, refractory (adjunctive therapy or monotherapy) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>FDA-approved for Lennox-Gastaut syndrome and resistant absence seizures; however, also used off label as adjunctive or bridge therapy in other seizure types, including myoclonic and atonic seizures and drug-resistant epilepsy syndromes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28073923','lexi-content-ref-Schacter.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28073923','lexi-content-ref-Schacter.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy:</i> Initial: 0.5 to 1.5 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9203243','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9203243','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adjunctive therapy</i>: Initial: 0.5 to 1 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schacter.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schacter.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosage adjustment: May increase dose based on response and tolerability in increments of 0.5 to 1 mg every 3 to 7 days to usual maintenance dose of 2 to 8 mg/day in 1 to 2 divided doses; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9203243','lexi-content-ref-Schacter.2020','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9203243','lexi-content-ref-Schacter.2020','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b2d9655-3745-4090-b9e4-e090f9c7caad">Tardive dyskinesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tardive dyskinesia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For reduction of dyskinesia and anxiety in milder forms of tardive dyskinesia in conjunction with appropriate therapy modification(s) such as tapering/discontinuing offending drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Liang.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Liang.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 mg/day; increase daily dose based on response and tolerability by 0.5 mg every 5 days up to 4 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6109454','lexi-content-ref-Liang.2020','lexi-content-ref-1969244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6109454','lexi-content-ref-Liang.2020','lexi-content-ref-1969244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cafbc8a-abd9-42c0-9a5e-50ae32938929">Vertigo, acute episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo, acute episodes (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.25 to 0.5 mg every 8 to 12 hours as needed for up to 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2020','lexi-content-ref-14763236']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2020','lexi-content-ref-14763236'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low or moderate dose, no concerns for benzodiazepine use disorder:</b> Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-VADoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-VADoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended or high-dose therapy, or suspected benzodiazepine use disorder:</b> Taper total daily dose by ~25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADoD.2'])">Ref</a></span>). Reduce dose more rapidly in the beginning, and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VADoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VADoD.2'])">Ref</a></span>). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VADoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VADoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991071"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Clonazepam pharmacokinetics have not been formally evaluated in patients with kidney impairment; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Initial: No dosage adjustment necessary for any degree of kidney impairment (&lt;2% eliminated in the urine as unchanged drug) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27060684','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27060684','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate based on tolerability and response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be substantially dialyzed (highly protein bound, large V<sub>d</sub>): No supplemental dose or initial dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate based on tolerability and response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be substantially dialyzed (highly protein bound, large V<sub>d</sub>): Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate based on tolerability and response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate based on tolerability and response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate based on tolerability and response.</p></div>
<div class="block doha drugH1Div" id="F50988332"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Clonazepam undergoes hepatic metabolism. Contraindicated in patients with significant hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F56287443"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anterograde amnesia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines can impair explicit memory and produce short-term <b>anterograde amnesia</b> (ie, memory of information or events after drug administration). Retrograde amnesia (ie, events or information prior to drug administration) is unaffected. However, the magnitude of the amnesic effect from benzodiazepines differs among the various agents, depending on their pharmacokinetic/pharmacodynamic properties, route of administration, and dose. Anterograde amnesia is associated with higher doses, IV administration, and benzodiazepines with faster absorption and higher potency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1684055','lexi-content-ref-20138190','lexi-content-ref-23789008','lexi-content-ref-1357612','lexi-content-ref-10519733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1684055','lexi-content-ref-20138190','lexi-content-ref-23789008','lexi-content-ref-1357612','lexi-content-ref-10519733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related. Benzodiazepines, including clonazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex is composed of five subunits, each with multiple isoforms. Each receptor complex contains a benzodiazepine-binding site, which is classified into several types, based on the alpha subunit isoforms and clinical effects related to each type. The BZ1 receptor type, containing the alfa1 subunit isoform, is highly concentrated in the cortex, thalamus, and cerebellum, and is responsible for benzodiazepine-associated anterograde amnesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; during chronic benzodiazepine administration, tolerance appears to develop, and memory impairment is limited to a window of 90 minutes following each dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific benzodiazepine: Clonazepam, despite its high potency, is less likely to cause anterograde amnesia due to its low lipid solubility (resulting in slower absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-23789008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-23789008'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008','lexi-content-ref-6151849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008','lexi-content-ref-6151849'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clonazepam can cause significant <b>drowsiness </b>and<b> fatigue</b>. Tolerance usually develops to its sedative effects. In addition, clonazepam has been shown to cause <b>ataxia </b>(usually transient) and <b>psychomotor impairment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4219957','lexi-content-ref-6424398','lexi-content-ref-976134','lexi-content-ref-22536226','lexi-content-ref-2106335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4219957','lexi-content-ref-6424398','lexi-content-ref-976134','lexi-content-ref-22536226','lexi-content-ref-2106335'])">Ref</a></span>). Benzodiazepines, in general, are associated with an increased risk of motor vehicle accidents and falls (particularly in older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-6424398','lexi-content-ref-10519733','lexi-content-ref-32536331','lexi-content-ref-22059800','lexi-content-ref-11314681','lexi-content-ref-2106335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18570226','lexi-content-ref-28539164','lexi-content-ref-6424398','lexi-content-ref-10519733','lexi-content-ref-32536331','lexi-content-ref-22059800','lexi-content-ref-11314681','lexi-content-ref-2106335'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Sedation is dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4219957','lexi-content-ref-976134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4219957','lexi-content-ref-976134'])">Ref</a></span>); benzodiazepines, including clonazepam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. Benzodiazepine-associated sedation are mediated by the alpha 1-containing GABA-A receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789008','lexi-content-ref-21353710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789008','lexi-content-ref-21353710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Sedating effects:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22059800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22059800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4219957','lexi-content-ref-976134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4219957','lexi-content-ref-976134'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Titrating the initial dose too rapidly (gradual titration and dividing the dosing is preferred) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-976134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-976134'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant use of other CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385731'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Paradoxical reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paradoxical reactions</b>, sometimes referred to as disinhibitory reactions or behavioral disinhibition, have been reported in children, adults, and older adults with benzodiazepine use, particularly in those with risk factors. Reactions are relatively uncommon and have been characterized in a number of ways, including increased talkativeness, excitement, restlessness, hyperactivity, sleep disturbances<b>,</b> hostility, rage, agitation, and/or aggressive behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-10653202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186578','lexi-content-ref-1677237','lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-10653202'])">Ref</a></span>). In children, paradoxical reactions to benzodiazepines, particularly midazolam, have been most commonly described as agitation, restlessness, inconsolable crying, screaming, disorientation, and/or excitement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1904374','lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1904374','lexi-content-ref-15460178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (potentially, although may also be idiosyncratic); exact mechanism is unclear due to limited evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bond.1998','lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bond.1998','lexi-content-ref-15460178'])">Ref</a></span>). One hypothesis has suggested that increased GABAergic activity in the brain from benzodiazepines causes a decrease in the restraining influence of the frontal cortex, thereby causing excitement, hostility, and rage. An additional proposed mechanism is that benzodiazepines can reduce serotonergic neurotransmission, subsequently causing aggressive behavior. Another mechanism is that in select patients with genetic variations in the GABA-A receptors, there is decreased GABA transmission with benzodiazepines which results in neuronal overexcitation manifested clinically as a paradoxical reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines, in general:</p>
<p style="text-indent:-2em;margin-left:8em;">Age-related (extremes of age):</p>
<p style="text-indent:-2em;margin-left:10em;">• Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-10519733','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Disease- or condition-related:</p>
<p style="text-indent:-2em;margin-left:10em;">• Past history of aggressive behavior or violence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Alcoholism or history of alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Psychiatric or personality disorders, including affective disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Patient-related:</p>
<p style="text-indent:-2em;margin-left:10em;">• Genetic predisposition (potential risk factor) (ie, variability in the density of the GABA-benzodiazepine receptors throughout the brain, a persistence of a juvenile pattern of benzodiazepine response in adulthood, or multiple allelic forms of the receptors with varying affinities for benzodiazepines have all been suggested as potentially playing a role) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15460178','lexi-content-ref-29723722','lexi-content-ref-3661967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Other potential risk factors: <b>Note: </b>No established risk factors since evidence is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186578'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Higher doses (likely a risk, but not firmly established) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3137624','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3137624','lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Parenteral benzodiazepine administration (potential risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29723722'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Specific benzodiazepines (potential risk): Benzodiazepines with a higher potency (eg, clonazepam) and/or a short half-life (eg, alprazolam) are believed to carry an increased risk; however, it has also been suggested that there is no difference in risk among the various benzodiazepines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bond.1998','lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bond.1998','lexi-content-ref-3137624','lexi-content-ref-12186578','lexi-content-ref-29723722'])">Ref</a></span>) Of note, clonazepam is considered to have a relatively long half-life (usually reported at &gt;24 hours for adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-10653202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-10653202'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Therapeutic use of benzodiazepines, including clonazepam, is associated with a <b>withdrawal syndrome </b>in children and adults<b>, </b>particularly following abrupt or overly rapid discontinuation following regular use. Benzodiazepine-associated withdrawal symptoms can include new withdrawal symptoms or rebound symptoms, both of which are typically transient, short-lasting, and reversible. A persistent post-withdrawal disorder, which can be long-lasting, severe, and potentially irreversible, has also been described. In general, withdrawal symptoms are typically mild and characterized as anxiety, panic attacks, restlessness, insomnia and other sleep disturbances, irritability, poor concentration, confusion, nausea/vomiting, weight loss, tremor, diaphoresis, tachycardia, and muscle pain/stiffness. Severe symptoms such as seizure and psychosis may also rarely occur following abrupt discontinuation. Severe withdrawal may be fatal. Data are limited on persistent post-withdrawal disorders, but cognitive impairment; depression; anxiety; sensory disturbances (eg, tinnitus, paresthesia, skin sensations); motor disturbances (eg, muscle pain, weakness, spasms); and GI disturbances have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7894837','lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-20473065','lexi-content-ref-10519733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7894837','lexi-content-ref-3092053','lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-20473065','lexi-content-ref-10519733'])">Ref</a></span>). For clonazepam specifically, there are also rare case reports of new-onset withdrawal <b>catatonia</b> occurring after abrupt withdrawal of chronic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26949118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26949118'])">Ref</a></span>). Severity, onset, and duration of any benzodiazepine withdrawal syndrome varies based on several factors, such as specific benzodiazepine administered (and its half-life), dose, and duration of use. However, in general, new withdrawal symptoms typically resolve within 2 to 4 weeks and rebound symptoms may last 3 weeks, but persistent post-withdrawal symptoms may last &gt;6 weeks and take 6 to 12 months to completely resolve, and in some cases, persist for years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; exact mechanisms are complex and unclear, but chronic exposure to benzodiazepines alters GABAergic neurotransmission (up/down regulation of gamma-aminobutyric acid [GABA]-A receptor subunits) and rapid or abrupt withdrawal results in underactivity of inhibitory GABA functions subsequently increasing excitatory nervous activity and likely contributing to symptoms associated with withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19900604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19900604'])">Ref</a></span>). A role of glutamate receptors, including N-methyl-D aspartate (NMDA)-, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptors, and metabotropic glutamate (mGlu) receptors, has also been suggested. In mice and rat studies, antagonists for glutamate receptors have shown the ability to potently suppress the withdrawal signs caused by chronic benzodiazepine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12725868','lexi-content-ref-10580363','lexi-content-ref-15266351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of symptoms usually occurs within the first day following abrupt withdrawal of short- or intermediate-acting benzodiazepines (such a lorazepam). Long-acting benzodiazepines (such as diazepam) are usually associated with an initial onset of withdrawal symptoms 5 days following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053'])">Ref</a></span>). Due to clonazepam’s longer half-life (range in adults: 17 to 60 hours) and slower elimination, clonazepam is usually associated with withdrawal symptoms that are more delayed in onset; in a small number of patients receiving clonazepam for seven consecutive nights for insomnia, significant rebound insomnia was observed on the third withdrawal night following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2066457','lexi-content-ref-8848810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2066457','lexi-content-ref-8848810'])">Ref</a></span>). In general, persistent post-withdrawal disorder associated with psychotropic medications (eg, benzodiazepines) have an onset ranging from 24 hours to 6 weeks following a decrease, discontinuation, or switch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Benzodiazepines, in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Abrupt discontinuation (rather than gradual dosage reduction) of a benzodiazepine used long-term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3092053','lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3092053','lexi-content-ref-32259826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9559604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9559604'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Chronic dosing (ie, intermittent dosing may reduce the risk of withdrawal symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31271339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31271339'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Long treatment durations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1980689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1980689'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Withdrawal-associated seizure: Predisposed patients (eg, brain damage, alcohol abuse, history of seizure, or those taking medications that lower the seizure threshold) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Clonazepam specifically:</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific benzodiazepine: Benzodiazepines with a relatively longer half-life (usually reported at &gt;24 hours in adults), such as clonazepam, are usually associated with fewer (and potentially less severe) rebound and withdrawal symptoms, particularly if tapered appropriately. High-potency benzodiazepines with short and intermediate half-lives generally have a higher risk for rebound, withdrawal reactions, and dependence compared to long-acting agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-20473065','lexi-content-ref-1686752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15078112','lexi-content-ref-32259826','lexi-content-ref-20473065','lexi-content-ref-1686752'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Ultraslow acetylation of the clonazepam metabolite by the N-acetyltransferase (NAT2) enzyme (potential risk factor; single case report) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30520338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30520338'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F153345"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions reported in patients with panic disorder, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Ataxia (seizure disorder: ~30%; panic disorder: 1% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 1</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, behavioral problems (seizure disorder: ~25%), dizziness (5% to 12%), drowsiness (seizure disorder: ~50%; panic disorder: 26% to 50%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Drowsiness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Clonazepam: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to &lt;3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">96</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to &lt;2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "coordination abnormal"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to &lt;3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "coordination abnormal"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to &lt;2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "coordination abnormal"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">96</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "coordination abnormal"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">~30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seizure disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Clonazepam: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to &lt;3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to &lt;2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">96</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">~50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seizure disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), constipation (3% to 5%), decreased appetite (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (3% to 6%), impotence (≤3%), urinary frequency (1% to 2%), urinary tract infection (2%), vaginitis (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (1% to 2%), decreased mental acuity (2% to 4%), delayed ejaculation (1% to 2%), depression (6% to 8%), dysarthria (2% to 4%), emotional lability (2%), fatigue (6% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 3</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, memory impairment (4% to 5%), nervousness (3% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Clonazepam: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonazepam)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">&lt;1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">96</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to &lt;3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to &lt;2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">129</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">294</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (2%), cough (2% to 4%), pharyngitis (2% to 3%), rhinitis (2% to 4%), sinusitis (4% to 8%), upper respiratory tract infection (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1% (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ankle edema, chest pain, edema, flushing, leg thrombophlebitis, orthostatic hypotension, palpitations, pedal edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne flare, alopecia, burning sensation of skin, cellulitis, contact dermatitis, dermal hemorrhage, dermatological reaction, excoriation of skin, pruritus, pustular rash, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gout, increased libido, increased thirst, loss of libido, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, ageusia, dyspepsia, flatulence, frequent bowel movements, gastric distress, gastrointestinal inflammation, heartburn, hemorrhoids, hunger, increased appetite, motion sickness, sialorrhea, toothache</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder dysfunction, cystitis, dysuria, ejaculatory disorder, irregular menses, mastalgia, pelvic pain, urinary incontinence, urinary retention, urinary tract hemorrhage, urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, fungal infection, herpes simplex infection, infectious mononucleosis, streptococcal infection, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, alcohol intoxication, ankle pain, anxiety, apathy, depersonalization, disinhibition (organic), disturbance in attention, excitement, falling, heavy headedness, hyperactive behavior, hypertonia, hypoesthesia, illusion, increased dream activity, insomnia, malaise, migraine, nightmares, outbursts of anger, pain, paresis, paresthesia, shivering, sleep disorder, slowed reaction time, suicidal ideation, twitching, twitching of eye, vertigo, yawning</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal<b>: </b>Arthralgia, back pain, bone fracture, foot pain, jaw pain, knee effusion, knee pain, lower back pain, lower extremity pain, lower limb cramp, muscle cramps, muscle strain, neck pain, shoulder pain, sprain, tendinopathy, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, eye irritation, hordeolum, periorbital edema, visual disturbance, visual field defect, xerophthalmia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, otitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, epistaxis, exacerbation of asthma, hoarseness, pleurisy, pneumonia, sneezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury, burn, fever, wound</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug dependence, suicidal tendencies, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Paradoxical reaction (including, agitation, hallucination, hostility, irritability, sleep disturbance, vivid dreams)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (Munoli 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hirsutism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, coated tongue, diarrhea, encopresis, gastritis, gingival pain, nausea, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, eosinophilia, leukopenia, lymphadenopathy, pancytopenia (Bautista-Quach 2010), thrombocytopenia (Veall 1975)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly, increased serum alkaline phosphatase (transient), increased serum transaminases (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior (increased oppositional behavior) (Waslick 2006), anterograde amnesia, aphonia, catatonia (with withdrawal) (Oldham 2016), choreiform movements, coma, glassy-eyed appearance, headache, hemiparesis, hypotonia, hysteria, myasthenia, parasomnias (sleep-related eating disorder) (Ghosh 2018), psychomotor impairment (Wilden 1990), psychosis, slurred speech</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dysdiadochokinesia, muscle injury (myotoxicity) (Han 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal eye movements, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Chest congestion, respiratory depression (Channing 2012), rhinorrhea, upper respiratory system symptoms (hypersecretion)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Physical health deterioration</p></div>
<div class="block coi drugH1Div" id="F153362"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to clonazepam, other benzodiazepines, or any component of the formulation; significant liver disease; acute narrow-angle glaucoma</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe respiratory insufficiency; sleep apnea syndrome; myasthenia gravis</p></div>
<div class="block war drugH1Div" id="F153342"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: May be used in patients with open angle glaucoma who are receiving appropriate therapy; contraindicated in acute narrow angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; accumulation likely to occur. Contraindicated in patients with significant hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersalivation: Clonazepam may produce an increase in salivation; use with caution in patients who have difficulty handling secretions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; may have a porphyrogenic effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Clonazepam metabolites are renally eliminated; however, the metabolites are inactive or weakly active; therefore, the clinical significance of metabolite accumulation has not been determined. Caution may be warranted if using in patients with kidney impairment, particularly if they may be more susceptible to clonazepam-related adverse effects (eg, elderly, use of concomitant medications with CNS effects).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flumazenil: Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult patients: Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>
<i>Dosage form specific issues:</i></b></i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Worsening of seizures may occur when added to patients with multiple seizure types. Loss of antiseizure activity may occur (typically within 3 months of initiation); dose adjustment may be necessary. Periodically reevaluate the long-term usefulness of clonazepam for the individual patient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Clonazepam is a long half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the antiseizure effects. It does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p></div>
<div class="block foc drugH1Div" id="F153353"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 0.5 mg [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 0.5 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 0.5 mg [DSC] [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 1 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 1 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 2 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">KlonoPIN: 2 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F153338"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F153365"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (clonazePAM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.125 mg (per each): $1.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $1.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $1.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $1.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $2.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (clonazePAM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.63 - $0.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.63 - $0.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (KlonoPIN Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $3.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $3.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $4.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866394"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivotril: 0.5 mg, 2 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg</p></div>
<div class="block exp drugH1Div" id="F153360"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>0.1 mg/mL Oral Suspension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 0.1 mg/mL oral suspension may be made with tablets and one of three different vehicles (cherry syrup; a 1:1 mixture of Ora-Sweet and Ora-Plus; or a 1:1 mixture of Ora-Sweet SF and Ora-Plus). Crush six 2 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well" and "protect from light". Stable for 60 days when stored in amber prescription bottles in the dark at room temperature or refrigerated.</p>
<div class="reference">Allen LV Jr and Erickson MA 3rd. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(16):1944-1949.<span class="pubmed-id">8862208</span></div>
</div>
<div class="block csi drugH1Div" id="F153428"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block admp drugH1Div" id="F52612441"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: To reduce somnolence, administration of one dose at bedtime may be desirable.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Swallow whole with water.</p></div>
<div class="block adm drugH1Div" id="F153358"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">To reduce somnolence, administration of one dose at bedtime may be desirable.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Swallow whole with water.</p></div>
<div class="block hazard drugH1Div" id="F49130945"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F16031439"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block meg drugH1Div" id="F10815684"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F017533s062lbl.pdf%23page%3D24&amp;token=UAL0CFFynMMZMyOokFyo9FmWTfZEiDrR23tML8iR%2BE77ii2SFL8fHyHy1lZwVTbertcqDWHigfVKs7cpz5mzAyEr%2BAtHsM%2Fp%2BWEttpWrWG%2BJZ1MD7t0mmmQZMTXBykY9&amp;TOPIC_ID=13170" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017533s062lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53566124"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Monotherapy or adjunct therapy in the treatment of Lennox-Gastaut syndrome (akinetic and myoclonic seizures) and absence seizures unresponsive to succinimides (FDA approved in infants, children, adolescents, and adults); treatment of panic disorder with or without agoraphobia (FDA approved in ages ≥18 years and adults); has also been used for myoclonic seizures.</p></div>
<div class="block mst drugH1Div" id="F153435"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ClonazePAM may be confused with ALPRAZolam, cloBAZam, cloNIDine, clorazepate, cloZAPine, LORazepam</p>
<p style="text-indent:-2em;margin-left:4em;">KlonoPIN may be confused with cloNIDine, clorazepate, cloZAPine, LORazepam</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Clonazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. Older adults also have a slower metabolism of long-acting benzodiazepines (eg, clonazepam). However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F153421"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F153347"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of ClonazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of ClonazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of ClonazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vigabatrin: May enhance the CNS depressant effect of ClonazePAM. Vigabatrin may increase the serum concentration of ClonazePAM.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F55438669"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block rep_considerations drugH1Div" id="F58006032"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F153366"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clonazepam crosses the placenta (Schmidt 2023).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to clonazepam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy (BAP [McAllister-Williams 2017]; Larsen 2015), and when a benzodiazepine is needed, the use of clonazepam is not preferred. If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">When treating pregnant patients for seizure disorders, monotherapy with the lowest effective dose and avoidance medications known to have a high incidence of teratogenic effects is recommended (Harden 2009; Wlodarczyk 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to clonazepam is ongoing. Patients exposed to clonazepam during pregnancy are encouraged to enroll themselves in the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53566125"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of suicidality (eg, anxiety, depression, behavior changes). Long-term use: CBC with differential, platelets, liver and renal function</p></div>
<div class="block rerp drugH1Div" id="F53565873"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Relationship between serum concentration and seizure control is not well established; predose serum concentrations are recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Proposed therapeutic levels: 20 to 85 ng/mL (Mikati 2020; Patsalos 2018); in children, a trial for absence seizures reported 13 to 72 ng/mL and a trial for partial seizures reported 14 to 68 ng/mL as the observed therapeutic range (Dreifuss 1975).</p></div>
<div class="block pha drugH1Div" id="F153341"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Intermediate- to long-acting benzodiazepine (based on half-life) (Griffin 2013). The exact mechanism is unknown, but believed to be related to its ability to enhance the activity of GABA; suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex.</p></div>
<div class="block phk drugH1Div" id="F153361"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~20 to 40 minutes (Hanson 1972).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Classified as an intermediate- to long-acting benzodiazepine; classification based on benzodiazepines with a half-life of 12 to 40 hours as intermediate-acting and those with a half-life &gt;40 hours as long-acting (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Indication-specific duration: Motor seizures: Infants and young children: 6 to 8 hours; older children: 6 to 12 hours (Hanson 1972).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly and completely absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Children: V<sub>d</sub>: 1.5 to 3 L/kg (Walson 1996); Adults: V<sub>d</sub>: 1.5 to 6.4 L/kg (Walson 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~85%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via glucuronide and sulfate conjugation; undergoes nitroreduction to 7-aminoclonazepam, followed by acetylation to 7-acetamidoclonazepam; nitroreduction and acetylation are via CYP3A4; metabolites undergo glucuronide and sulfate conjugation (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Neonates: 22 to 81 hours (Patsalos 2018); Children: 22 to 33 hours (Walson 1996); Adults: 17 to 60 hours (Walson 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;2% as unchanged drug); metabolites excreted as glucuronide or sulfate conjugates.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F153368"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alerion | Ciclox | Clonagin | Clonasedan | Clonax | Clonazepam Cevallos | Clonazepam Denver Farma | Clonazepam Fabra | Clonazepam Genpharma | Clonazepam kilab | Clonazepam Lba | Clonazepam Lemax | Clonazepam northia | Clonazepam puntanos | Clonazepam rospaw | Clonazepan dosa | Clonazepan duncan | Clonazepan Monte Verde | Cloner | Diocam | Edictum | Induzepam | Leptic chobet | Nazepamclo | Neuryl | Olimer | Placidiax | Quazemic | Ribocler | Riuclonaz | Rivotril | Sedovanon | Sensaton | Solfidin | Tecepin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Paxam | Rivotril</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arotril | Clepam | Cloma | Clon | Clonatril | Clonil | Clonium | Clonzy | Clopam | Cloron | Comfy | Conpan odt | Denixil | Disopan | Epiclon | Lonapam | Lonazep | Miraclon | Myotril | Pandura | Pase | Rivo | Rivotril | Xioclon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Clonareks | Clonazepam TZF | Rivotril</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clonetril | Clonotril | Clopam | Epileptil | Navotrax | Rivotril | Uni Clonazepax | Zilepam</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acepran | Bejowa | Celaxin | Clonapam | Clozanil | Crismol | Neuryl | Ravotril | Ropsil | Valpax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jing kang | Rivotril</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam humax | Clonazepam winthrop | Cloxal | Clozam | Coquan | Rivotril | Sedatril | Valpax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Rivotril</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam neuraxpharm | Rivotril</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ansiocol | Clonagin | Clonapam | Clonex cd | Diocam | Olan | Ribosan | Rivotril | Valpax</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acepran | Clonagin | Coquan | Kriadex | Neuryl | Rivotril | Valpax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Rivotril</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amotril | Apetryl | Clopam | Rivotril | Ronatril</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam biomed | Clonazepam neuraxpharm | Rivotril</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rivatril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam auden | Clonazepam neuraxpharm | Clonazepam Thame | Rivotril</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aklonil | Clonazepamum/tzf | Clonotril | Rivotril</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pms clonazepam | Rivotril</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Clonapam | Clonazepamum tarchomin | Clonogal | Rivotril</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Riklona | Rivotril</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam rosemont | Rivotril</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Clonex | Rivotril</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afd clona | Alcona | Anxipam md | Anxipar | Aplaz | Calmstay | Cergo | Cleps | Cloam | Cloapax | Clonabris | Clonafit | Clonam | Clonapax | Clonapax md | Clonarestil md | Clonaril | Clonasig | Clonax | Clonaxyl | Clonis md | Clonorest | Clonotril | Clonova | Clopam | Clopem | Clopz | Clorom 0.5 md | Closed | Closis | Closis md | Clotas | Clotrin | Cloze | Cloze md | Clozen | Clozep | Clozepam | Clozil | Cnzep | Convaclon | Emcloz | Eminaz | Epcon | Epitril | Epizam | Klonaz | Linotril | Logen | Lonacen | Lonafest | Lonavib | Lonazep | Lonna | Lozep | Meloprax | Melzap | Naaz | Naza | Noanx | Norep | Odzepam | Ona md | Onatril MD | Ozepam | Petril | Petril md | Prozepton md | Restovis | Rivotril | Sezolep | Somnex | Strozip | Switril | Zap | Zapiz | Zapnax md | Zee | Zeficar | Zena | Zepam | Zepam MD | Zocam-C | Zona</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Clonatril | Rivoram | Rivotril</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Landsen | Rivotril</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rivotril | Whanin clonazepam | Wi clonazepam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Rivotril</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Rivotril</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Klonopin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anzanera | Apoclopam | Clozenek | Clozer | Gabaclotec | Gabaclotec S | Kalinawa | Kenoket | Klodex | Kriadex | Pamazarina | Panazeclox | Retrozan | Rimastine | Rivotril | Zymanta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rivopam | Rivotril</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clonazepam Sandoz | Clonazepam TZF | Rivotril</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Paxam | Rivotril</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acepran | Anzatax | Clonapam | Clonazepan | Clonazz | Clopam | Coquan | Kriadex | Lomequin | Lonazep | Maxipax | Neuropasil | Neuryl | Neuryl plus | Rivopax | Rivotril | Sedapan | Sediflam | Zapiz | Zatrix</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Clonotril | Rivotril</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arsopam | C pam | Clepam | Clonaviz | Clonazee | Clonazerain | Clonze | Clonzi | Epitril | Epizep | Klozepam | Lonese | Magura | Medyo | Nazepam | Rakapam | Rivotril | Rospam | Tovir | U clon | Zaron</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Clonazepamum | Rivotril</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Klonopin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rivotril | Zepacla</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Biozepan | Blortem | Clomeg | Clonagin | Clonapam | Clonazepam heisecke | Clonazepam polimed | Clonazepam rospaw | Clonazepan dasanti | Clonazepan dima | Clonazepan phi | Clonoten | Clopan | Crucial | Edictum | Levonam | Neuryl | Neuryl 0,50 flash | Plenium | Quietal | Rivotril | Sedalium | Sedigalen | Sulivan | Suprasedan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rivotril | Rivotril Drops</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Clonotril</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Clonazepan | Rivotril</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pms clonazepam | Rivotril</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Iktorivil | Rivotril</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Clonotril | Rivotril</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Clonazepamum tzf | Rivotril</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Rivotril</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ancoril | Clonaril | Convolsil | Povanil | Prenarpil | Rivotril</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aklonil | Pms clonazepam | Rivotril</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rivoclon | Rivotril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aclonax | Clonopam | Ripam | Rivopam | Rivotril</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Antelepsin | Clonazepam ic</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Clonalgin | Clonapine | Clonapine odt | Clonazam | Clonazepam Edictum | Clonoten | Flozepan | Neuryl | Rivotril | Solfidin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clonac | Clonatril | Clonex | Clonzep | Rivotril | Valpax</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Alzocalm | Antaspan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Clonam | Rivotril</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Rivotril</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12725868">
<a name="12725868"></a>Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. <i>Pharmacol Ther</i>. 2003;98(2):171-195. doi:10.1016/s0163-7258(03)00029-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/12725868/pubmed" id="12725868" target="_blank">12725868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2009. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed May 24, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24122696">
<a name="24122696"></a>Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. <i>Clin Pharmacokinet</i>. 2014;53(1):29-49. doi:10.1007/s40262-013-0107-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/24122696/pubmed" id="24122696" target="_blank">24122696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900604">
<a name="19900604"></a>Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. <i>Ann Pharm Fr</i>. 2009;67(6):408-413. doi:10.1016/j.pharma.2009.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/19900604/pubmed" id="19900604" target="_blank">19900604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990368">
<a name="31990368"></a>Ayuga Loro F, Gisbert Tijeras E, Brigo F. Rapid versus slow withdrawal of antiepileptic drugs. <i>Cochrane Database Syst Rev</i>. 2020;1(1):CD005003. doi:10.1002/14651858.CD005003.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/31990368/pubmed" id="31990368" target="_blank">31990368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403‐439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders.<i> World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28073923">
<a name="28073923"></a>Bank AM, Lee JW, Krause P, Berkowitz AL. What to do when patients with epilepsy cannot take their usual oral medications. <i>Pract Neurol</i>. 2017;17(1):66‐70. doi:10.1136/practneurol-2016-001437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/28073923/pubmed" id="28073923" target="_blank">28073923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1355799">
<a name="1355799"></a>Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA. Effects of exposure to benzodiazepine during fetal life. <i>Lancet</i>. 1992;340(8821):694-696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1355799/pubmed" id="1355799" target="_blank">1355799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32267799">
<a name="32267799"></a>Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. <i>Otolaryngol Head Neck Surg</i>. 2020;162(suppl 2):S1-S55. doi:10.1177/0194599820909438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/32267799/pubmed" id="32267799" target="_blank">32267799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28248609">
<a name="28248609"></a>Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). <i>Otolaryngol Head Neck Surg</i>. 2017;156(3)(suppl):S1‐S47. doi:10.1177/0194599816689667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/28248609/pubmed" id="28248609" target="_blank">28248609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23897874">
<a name="23897874"></a>Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2013;81(5):463-469. doi:10.1212/WNL.0b013e31829d86b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/23897874/pubmed" id="23897874" target="_blank">23897874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390297">
<a name="10390297"></a>Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. <i>Pediatrics</i>. 1999;104(1):e11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10390297/pubmed" id="10390297" target="_blank">10390297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307041">
<a name="11307041"></a>Blin O, Simon N, Jouve E, et al. Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers. <i>Clin Neuropharmacol</i>. 2001;24(2):71-81. doi:10.1097/00002826-200103000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/11307041/pubmed" id="11307041" target="_blank">11307041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6109454">
<a name="6109454"></a>Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. <i>Am J Psychiatry</i>. 1981;138(2):189-193. doi:10.1176/ajp.138.2.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/6109454/pubmed" id="6109454" target="_blank">6109454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bond.1998">
<a name="Bond.1998"></a>Bond AJ. Drug-induced behavioural disinhibition: Incidence, mechanisms and therapeutic implications. <i>CNS Drugs</i>. 1998;9(1):41-57.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3137624">
<a name="3137624"></a>Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. <i>Psychopharmacology (Berl)</i>. 1988;95(3):369-373. doi:10.1007/BF00181949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3137624/pubmed" id="3137624" target="_blank">3137624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3080850">
<a name="3080850"></a>Bressman S, Fahn S. Essential myoclonus. <i>Adv Neurol</i>. 1986;43:287‐294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3080850/pubmed" id="3080850" target="_blank">3080850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9203243">
<a name="9203243"></a>Brodie MJ, Dichter MA. Established antiepileptic drugs. <i>Seizure</i>. 1997;6(3):159-174. doi:10.1016/s1059-1311(97)80001-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/9203243/pubmed" id="9203243" target="_blank">9203243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2839329">
<a name="2839329"></a>Brogden RN, Goa KL. Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity, and therapeutic use. <i>Drugs</i>. 1988;35(4):448-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/2839329/pubmed" id="2839329" target="_blank">2839329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7894837">
<a name="7894837"></a>Buchanan N, Sharpe C. Clonazepam withdrawal in 13 patients with active epilepsy and drug side effects. <i>Seizure</i>. 1994;3(4):271-275. doi:10.1016/s1059-1311(05)80174-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/7894837/pubmed" id="7894837" target="_blank">7894837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3092053">
<a name="3092053"></a>Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. <i>N Engl J Med</i>. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3092053/pubmed" id="3092053" target="_blank">3092053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35141811">
<a name="35141811"></a>Byun JI, Shin YY, Seong YA, et al. Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder. <i>Sleep Breath</i>. 2023;27(1):309-318. doi:10.1007/s11325-022-02572-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35141811/pubmed" id="35141811" target="_blank">35141811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559604">
<a name="9559604"></a>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. <i>Crit Care Med</i>. 1998;26(4):676-684. doi:10.1097/00003246-199804000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/9559604/pubmed" id="9559604" target="_blank">9559604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caviness.2020">
<a name="Caviness.2020"></a>Caviness JN. Treatment of myoclonus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention- deficit/hyperactivity disorders. <i>JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15078112">
<a name="15078112"></a>Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. <i>J Clin Psychiatry</i>. 2004;65(suppl 5):7-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/15078112/pubmed" id="15078112" target="_blank">15078112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clonazepam.1">
<a name="Clonazepam.1"></a>Clonazepam orally disintegrating tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clonazepam.2">
<a name="Clonazepam.2"></a>Clonazepam 0.5 mg/5 mL solution [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clonazepam.3">
<a name="Clonazepam.3"></a>Clonazepam 2 mg/5 mL solution [summary of product characteristics]. Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1904374">
<a name="1904374"></a>Commander M, Green SH, Prendergast M. Behavioural disturbances in children treated with clonazepam. <i>Dev Med Child Neurol</i>. 1991;33(4):362-363. doi:10.1111/j.1469-8749.1991.tb14889.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1904374/pubmed" id="1904374" target="_blank">1904374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259826">
<a name="32259826"></a>Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. <i>Psychother Psychosom</i>. 2020;89(5):283-306. doi:10.1159/000506868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/32259826/pubmed" id="32259826" target="_blank">32259826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19. 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1684055">
<a name="1684055"></a>Curran HV. Benzodiazepines, memory and mood: a review. <i>Psychopharmacology (Berl)</i>. 1991;105(1):1-8. doi:10.1007/BF02316856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1684055/pubmed" id="1684055" target="_blank">1684055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23985170">
<a name="23985170"></a>Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. <i>Ital J Pediatr</i>. 2013;39:50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/23985170/pubmed" id="23985170" target="_blank">23985170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8120156">
<a name="8120156"></a>Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. <i>J Clin Psychopharmacol</i>. 1993;13(6):423‐428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/8120156/pubmed" id="8120156" target="_blank">8120156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18570226">
<a name="18570226"></a>Dawson J, Boyle J, Stanley N, Johnsen S, Hindmarch I, Skene DJ. Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance. <i>Hum Psychopharmacol</i>. 2008;23(7):605-13. doi:10.1002/hup.961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/18570226/pubmed" id="18570226" target="_blank">18570226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28539164">
<a name="28539164"></a>Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: A systematic review. <i>Maturitas</i>. 2017;101:17-22. doi:10.1016/j.maturitas.2017.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/28539164/pubmed" id="28539164" target="_blank">28539164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. <i>CNS Drugs</i>. 2008;22(12):1021-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1089913">
<a name="1089913"></a>Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S. Serum clonazepam concentrations in children with absence seizures. <i>Neurology</i>. 1975;25(3):255-258. doi:10.1212/wnl.25.3.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1089913/pubmed" id="1089913" target="_blank">1089913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4219957">
<a name="4219957"></a>Edwards VE. Side effects of clonazepam therapy. <i>Proc Aust Assoc Neurol</i>. 1974;11:199-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/4219957/pubmed" id="4219957" target="_blank">4219957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22233697">
<a name="22233697"></a>Fang M, Chen H, Li LH, et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. <i>Int Clin Psychopharmacol</i>. 2012;27(2):107‐113. doi:10.1097/YIC.0b013e32834fc431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22233697/pubmed" id="22233697" target="_blank">22233697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26940460">
<a name="26940460"></a>Fernández-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. <i>Sleep</i>. 2016;39(1):121‐132. doi:10.5665/sleep.5332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/26940460/pubmed" id="26940460" target="_blank">26940460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4022513">
<a name="4022513"></a>Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. <i>Obstet Gynecol</i>. 1985;66(3)(suppl):34S-35S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/4022513/pubmed" id="4022513" target="_blank">4022513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry</i>. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2020">
<a name="Furman.2020"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14763236">
<a name="14763236"></a>Ganança MM, Caovilla HH, Ganança FF, et al. Clonazepam in the pharmacological treatment of vertigo and tinnitus. <i>Int Tinnitus J</i>. 2002;8(1):50‐53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/14763236/pubmed" id="14763236" target="_blank">14763236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26912127">
<a name="26912127"></a>Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. <i>World J Biol Psychiatry</i>. 2016;17(2):86‐128. doi:10.3109/15622975.2015.1132007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/26912127/pubmed" id="26912127" target="_blank">26912127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20138190">
<a name="20138190"></a>Giersch A, Boucart M, Elliott M, Vidailhet P. Atypical behavioural effects of lorazepam: clues to the design of novel therapies? <i>Pharmacol Ther</i>. 2010;126(1):94-108. doi:10.1016/j.pharmthera.2010.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/20138190/pubmed" id="20138190" target="_blank">20138190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta- analysis. <i>J Clin Psychiatry</i>. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385731">
<a name="29385731"></a>Guina J, Merrill B. Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives. <i>J Clin Med</i>. 2018;7(2):17. doi:10.3390/jcm7020017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29385731/pubmed" id="29385731" target="_blank">29385731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4554096">
<a name="4554096"></a>Hanson RA, Menkes JH. A new anticonvulsant in the management of minor motor seizures. <i>Dev Med Child Neurol</i>. 1972;14(1):3-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/4554096/pubmed" id="4554096" target="_blank">4554096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30520338">
<a name="30520338"></a>Ho TT, Gupta SV, Sanchez-Valle A. Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator. <i>Pharmacogenomics</i>. 2019;20(2):69-73. doi:10.2217/pgs-2018-0145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/30520338/pubmed" id="30520338" target="_blank">30520338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36515157">
<a name="36515157"></a>Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. <i>J Clin Sleep Med</i>. 2023b;19(4):759-768. doi:10.5664/jcsm.10424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/36515157/pubmed" id="36515157" target="_blank">36515157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howell.2020">
<a name="Howell.2020"></a>Howell M, Schenck CH. Rapid eye movement sleep behavior disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. <i>Psychiatr Serv</i>. 2002;53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3753263">
<a name="3753263"></a>Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. <i>Arch Neurol</i>. 1986;43(10):1025‐1031. doi:10.1001/archneur.1986.00520100039012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3753263/pubmed" id="3753263" target="_blank">3753263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study.<i> Eur Neuropsychopharmacol.</i> 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9430502">
<a name="9430502"></a>Johnson GD. Medical management of migraine-related dizziness and vertigo. <i>Laryngoscope</i>. 1998;108(1, pt 2):1‐28. doi:10.1097/00005537-199801001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/9430502/pubmed" id="9430502" target="_blank">9430502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186578">
<a name="12186578"></a>Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. <i>Am J Ment Retard</i>. 2002;107(5):376-410. doi:10.1352/0895-8017(2002)107&lt;0376:BBSERA&gt;2.0.CO;2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/12186578/pubmed" id="12186578" target="_blank">12186578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2066457">
<a name="2066457"></a>Kales A, Manfredi RL, Vgontzas AN, Baldassano CF, Kostakos K, Kales JD. Clonazepam: sleep laboratory study of efficacy and withdrawal. <i>J Clin Psychopharmacol</i>. 1991;11(3):189-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/2066457/pubmed" id="2066457" target="_blank">2066457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29898971">
<a name="29898971"></a>Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. <i>Neurology</i>. 2018;91(2):74-81. doi:10.1212/WNL.0000000000005755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29898971/pubmed" id="29898971" target="_blank">29898971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22504099">
<a name="22504099"></a>Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22504099/pubmed" id="22504099" target="_blank">22504099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6424398">
<a name="6424398"></a>Keränen T, Sivenius J. Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. <i>Acta Neurol Scand Suppl</i>. 1983;97:69-80. doi:10.1111/j.1600-0404.1983.tb01536.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/6424398/pubmed" id="6424398" target="_blank">6424398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35971024">
<a name="35971024"></a>Kienitz R, Kay L, Beuchat I, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. <i>CNS Drugs</i>. 2022;36(9):951-975. doi:10.1007/s40263-022-00940-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35971024/pubmed" id="35971024" target="_blank">35971024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klonopin.1">
<a name="Klonopin.1"></a>Klonopin tablets (clonazepam) [prescribing information]. Montgomery, AL: H2-Pharma LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448481">
<a name="27448481"></a>Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. <i>Sleep Med</i>. 2016;21:114‐120. doi:10.1016/j.sleep.2015.12.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/27448481/pubmed" id="27448481" target="_blank">27448481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Liang.2020">
<a name="Liang.2020"></a>Liang TL. Tardive dyskinesia: Prevention, treatment, and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1677237">
<a name="1677237"></a>Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. <i>Am J Psychiatry</i>. 1991;148(8):1099-100. doi:10.1176/ajp.148.8.1099a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1677237/pubmed" id="1677237" target="_blank">1677237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185. doi:10.1592/phco.24.13.1177.38089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marder.1">
<a name="Marder.1"></a>Marder S. Psychosis in adults: initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol</i>. 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1357612">
<a name="1357612"></a>Mejo SL. Anterograde amnesia linked to benzodiazepines. <i>Nurse Pract</i>. 1992;17(10):44, 49-50. doi:10.1097/00006205-199210000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1357612/pubmed" id="1357612" target="_blank">1357612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mikati.1">
<a name="Mikati.1"></a>Mikati MA, Tchapyjnikov D. Treatment of seizures and epilepsy. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 611.6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mojtabai.1">
<a name="Mojtabai.1"></a>Mojtabai R. Brief psychotic disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8990056">
<a name="8990056"></a>Montagna P, Provini F, Plazzi G, Liguori R, Lugaresi E. Propriospinal myoclonus upon relaxation and drowsiness: a cause of severe insomnia. <i>Mov Disord</i>. 1997;12(1):66‐72. doi:10.1002/mds.870120112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/8990056/pubmed" id="8990056" target="_blank">8990056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20473065">
<a name="20473065"></a>Nardi AE, Freire RC, Valença AM, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. <i>J Clin Psychopharmacol</i>. 2010;30(3):290-293. doi:10.1097/JCP.0b013e3181dcb2f3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/20473065/pubmed" id="20473065" target="_blank">20473065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. https://www.nice.org.uk/guidance/ng217. Published April 27, 2022. Accessed December 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol</i>. 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33449825">
<a name="33449825"></a>Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. <i>Breastfeed Med</i>. 2021;16(5):424-431. doi:10.1089/bfm.2020.0259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/33449825/pubmed" id="33449825" target="_blank">33449825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1980689">
<a name="1980689"></a>Nutt DJ. Pharmacological mechanisms of benzodiazepine withdrawal. <i>J Psychiatr Res</i>. 1990;24(suppl 2):105-110. doi:10.1016/0022-3956(90)90041-n<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1980689/pubmed" id="1980689" target="_blank">1980689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2905804">
<a name="2905804"></a>O'Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. <i>Psychopharmacol Ser</i>. 1988;6:146-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/2905804/pubmed" id="2905804" target="_blank">2905804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2499399">
<a name="2499399"></a>Obeso JA, Artieda J, Rothwell JC, Day B, Thompson P, Marsden CD. The treatment of severe action myoclonus. <i>Brain</i>. 1989;112(pt 3):765‐777. doi:10.1093/brain/112.3.765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/2499399/pubmed" id="2499399" target="_blank">2499399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26949118">
<a name="26949118"></a>Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: Two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. <i>Psychosomatics</i>. 2016;57(3):246-255. doi:10.1016/j.psym.2015.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/26949118/pubmed" id="26949118" target="_blank">26949118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10648440">
<a name="10648440"></a>Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. <i>Brain</i>. 2000;123(pt 2):331‐339. doi:10.1093/brain/123.2.331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10648440/pubmed" id="10648440" target="_blank">10648440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9845">
<a name="9845"></a>Pandit SK, Heisterkamp DV, Cohen PJ. Further studies of the anti-recall effect of lorazepam: A dose--time--effect relationship. <i>Anesthesiology</i>. 1976;45(5):495-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/9845/pubmed" id="9845" target="_blank">9845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-976134">
<a name="976134"></a>Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. <i>Drugs</i>. 1976;12(5):321-361. doi:10.2165/00003495-197612050-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/976134/pubmed" id="976134" target="_blank">976134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24399428">
<a name="24399428"></a>Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. <i>Am J Psychiatry</i>. 2014;171(1):44‐53. doi:10.1176/appi.ajp.2013.12101353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/24399428/pubmed" id="24399428" target="_blank">24399428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol</i>. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29723722">
<a name="29723722"></a>Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly - Case series. <i>Asian J Psychiatr</i>. 2018;35:8-10. doi:10.1016/j.ajp.2018.04.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29723722/pubmed" id="29723722" target="_blank">29723722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30791698">
<a name="30791698"></a>Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. <i>Can J Psychiatry</i>. 2019;64(6):388-399. doi:10.1177/0706743719828968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/30791698/pubmed" id="30791698" target="_blank">30791698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32536331">
<a name="32536331"></a>Richardson JK, Eckner JT, Kim H, Ashton-Miller JA. A clinical method of evaluating simple reaction time and reaction accuracy is sensitive to a single dose of lorazepam. <i>J Psychopharmacol</i>. 2020;34(8):920-925. doi:10.1177/0269881120915409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/32536331/pubmed" id="32536331" target="_blank">32536331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rivotril.2">
<a name="Rivotril.2"></a>Rivotril (clonazepam) [prescribing information]. North Ryde, NSW, Australia: Roche Australia; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rivotril.1">
<a name="Rivotril.1"></a>Rivotril (clonazepam) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6151849">
<a name="6151849"></a>Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. <i>Br J Clin Pharmacol</i>. 1984;18 Suppl 1(Suppl 1):45S-49S. doi:10.1111/j.1365-2125.1984.tb02581.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/6151849/pubmed" id="6151849" target="_blank">6151849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653202">
<a name="10653202"></a>Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. <i>J Clin Psychopharmacol</i>. 2000;20(1):7-11. doi:10.1097/00004714-200002000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10653202/pubmed" id="10653202" target="_blank">10653202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.2020a">
<a name="Roy-Byrne.2020a"></a>Roy-Byrne PP. Pharmacotherapy for panic disorder with or without agoraphobia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.2020b">
<a name="Roy-Byrne.2020b"></a>Roy-Byrne PP, Craske M. Management of panic disorder with or without agoraphobia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study.<i> Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi:10.1002/gps.4821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schacter.2020">
<a name="Schacter.2020"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36805301">
<a name="36805301"></a>Schmidt CT, Deligiannidis KM, Kittel-Schneider S, et al. Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood &amp; breast milk: a systematic review &amp; combined analysis. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2023;124:110733. doi:10.1016/j.pnpbp.2023.110733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/36805301/pubmed" id="36805301" target="_blank">36805301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003080">
<a name="15003080"></a>Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. <i>J Clin Psychiatry</i>. 2004;65(2):244‐248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/15003080/pubmed" id="15003080" target="_blank">15003080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3661967">
<a name="3661967"></a>Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? <i>Anaesth Intensive Care</i>. 1987;15(3):330-331. doi:10.1177/0310057X8701500314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3661967/pubmed" id="3661967" target="_blank">3661967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3366144">
<a name="3366144"></a>Söderman P, Matheson I. Clonazepam in breast milk. <i>Eur J Pediatr</i>. 1988;147(2):212-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/3366144/pubmed" id="3366144" target="_blank">3366144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25183382">
<a name="25183382"></a>Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/25183382/pubmed" id="25183382" target="_blank">25183382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8243361">
<a name="8243361"></a>Sugai K. Seizures with clonazepam: discontinuation and suggestions for safe discontinuation rates in children. <i>Epilepsia</i>. 1993;34(6):1089‐1097. doi:10.1111/j.1528-1157.1993.tb02138.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/8243361/pubmed" id="8243361" target="_blank">8243361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22059800">
<a name="22059800"></a>Sylvestre MP, Abrahamowicz M, Čapek R, Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. <i>Int Psychogeriatr</i>. 2012;24(4):577-586. doi:10.1017/S1041610211002031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22059800/pubmed" id="22059800" target="_blank">22059800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital national pregnancy registry for psychiatric medications. <i>Depress Anxiety</i>. 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353710">
<a name="21353710"></a>Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. <i>Trends Neurosci</i>. 2011;34(4):188-197. doi:10.1016/j.tins.2011.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/21353710/pubmed" id="21353710" target="_blank">21353710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969244">
<a name="1969244"></a>Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. <i>Am J Psychiatry</i>. 1990;147(4):445-451. doi:10.1176/ajp.147.4.445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1969244/pubmed" id="1969244" target="_blank">1969244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9168167">
<a name="9168167"></a>Tijssen MA, Schoemaker HC, Edelbroek PJ, Roos RA, Cohen AF, van Dijk JG. The effects of clonazepam and vigabatrin in hyperekplexia. <i>J Neurol Sci</i>. 1997;149(1):63‐67. doi:10.1016/s0022-510x(97)05378-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/9168167/pubmed" id="9168167" target="_blank">9168167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413800">
<a name="20413800"></a>Troester MM, Hastriter EV, Ng YT. Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures. <i>J Child Neurol</i>. 2010;25(12):1468-1472. doi:10.1177/0883073810368312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/20413800/pubmed" id="20413800" target="_blank">20413800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10580363">
<a name="10580363"></a>Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. <i>Jpn J Pharmacol</i>. 1999;81(1):1-6. doi:10.1254/jjp.81.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/10580363/pubmed" id="10580363" target="_blank">10580363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf</a>. Updated June 2017. Accessed March 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2">
<a name="VADoD.2"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11314681">
<a name="11314681"></a>van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology (Berl)</i>. 2001;154(2):189-197. doi:10.1007/s002130000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/11314681/pubmed" id="11314681" target="_blank">11314681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15266351">
<a name="15266351"></a>Van Sickle BJ, Xiang K, Tietz EI. Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. <i>Neuropsychopharmacology</i>. 2004;29(11):1994-2006. doi:10.1038/sj.npp.1300531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/15266351/pubmed" id="15266351" target="_blank">15266351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25837494">
<a name="25837494"></a>Veiby G, Bjørk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. <i>Seizure</i>. 2015;28:57-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/25837494/pubmed" id="25837494" target="_blank">25837494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future For Subtype-Selective GABA(A) Receptor Modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:416864.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24908194">
<a name="24908194"></a>Vlaskamp DR, Brouwer OF, Callenbach PM. Treatment of prolonged convulsive seizures in children; a single centre, retrospective, observational study. <i>Eur J Paediatr Neurol</i>. 2014;18(6):663-669. doi:10.1016/j.ejpn.2014.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/24908194/pubmed" id="24908194" target="_blank">24908194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31208784">
<a name="31208784"></a>Wallace A, Wirrell E, Payne E. Seizure rescue medication use among US pediatric epilepsy providers: a survey of the Pediatric Epilepsy Research Consortium. <i>J Pediatr</i>. 2019;212:111-116. doi:10.1016/j.jpeds.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/31208784/pubmed" id="31208784" target="_blank">31208784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8848810">
<a name="8848810"></a>Walson PD, Edge JH. Clonazepam disposition in pediatric patients. <i>Ther Drug Monit</i>. 1996;18(1):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/8848810/pubmed" id="8848810" target="_blank">8848810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27121429">
<a name="27121429"></a>Wang SM, Kim JB, Sakong JK, et al. The efficacy and safety of clonazepam in patients with anxiety disorder taking newer antidepressants: a multicenter naturalistic study. <i>Clin Psychopharmacol Neurosci</i>. 2016;14(2):177‐183. doi:10.9758/cpn.2016.14.2.177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/27121429/pubmed" id="27121429" target="_blank">27121429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: A systematic review. <i>Neurosci Biobehav Rev</i>. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16321725">
<a name="16321725"></a>Waslick B. Psychopharmacology interventions for pediatric anxiety disorders: a research update. <i>Child Adolesc Psychiatr Clin N Am</i>. 2006;15(1):51-71. doi:10.1016/j.chc.2005.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/16321725/pubmed" id="16321725" target="_blank">16321725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2106335">
<a name="2106335"></a>Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. <i>Br J Clin Pharmacol</i>. 1990;29(2):169-177. doi:10.1111/j.1365-2125.1990.tb03616.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/2106335/pubmed" id="2106335" target="_blank">2106335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271339">
<a name="31271339"></a>Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. <i>J Psychopharmacol</i>. 2019;33(8):923-947. doi:10.1177/0269881119855343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/31271339/pubmed" id="31271339" target="_blank">31271339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. <i>West J Emerg Med</i>. 2012;13(1):26‐34. doi:10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711424">
<a name="22711424"></a>Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. <i>Am J Med Genet A</i>. 2012;158A(8):2071-2090.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/22711424/pubmed" id="22711424" target="_blank">22711424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1686752">
<a name="1686752"></a>Wolf B, Griffiths RR. Physical dependence on benzodiazepines: differences within the class. <i>Drug Alcohol Depend</i>. 1991;29(2):153-156. doi:10.1016/0376-8716(91)90044-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/1686752/pubmed" id="1686752" target="_blank">1686752</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/WHO.1/pubmed" id="WHO.1" target="_blank">WHO.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17933619">
<a name="17933619"></a>Wusthoff CJ, Shellhaas RA, Licht DJ. Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity. <i>Pediatr Clin North Am</i>. 2007;54(5):709-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/abstract-text/17933619/pubmed" id="17933619" target="_blank">17933619</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13170 Version 648.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
